Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients

Overview

The purpose of this study is to evaluate efficacy of phlebotomy on insulin sensitivity as evaluated by euglycemic-hyperinsulinic clamp in insulin resistance-associated hepatic iron overload patients.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Investigator)
  • Study Primary Completion Date: October 2015

Detailed Description

The main objective of this study is to evaluate in patients with HSD effects of treatment with phlebotomy rules with lifestyle and dietary rules versus lifestyle modifications alone on peripheral insulin resistance (assessed by hyperinsulinemic clamp).

Secondary objectives are:

- to study in all patients with HSD the relationship between the amount of iron intrahepatic and degree of peripheral insulin resistance and liver before therapeutic intervention.

- to study and compare the effects of phlebotomy treatment versus no treatment on:

- Plasma levels of adipocytokines,

- Plasma concentrations of inflammatory markers and markers of insulin resistance,

- The serum ferritin,

- The post-hepatic clearance of insulin,

- The surface of the abdominal visceral fat and subcutaneous abdominal.

Interventions

  • Procedure: phlebotomy
    • 7 ml/kg without exceeding 500 mL
  • Behavioral: dietary and lifestyle counseling
    • dietary and lifestyle counseling

Arms, Groups and Cohorts

  • Experimental: Phlebotomy
    • phlebotomy associated with dietary and lifestyle counseling
  • Active Comparator: Lifestyle counseling
    • dietary and lifestyle counseling

Clinical Trial Outcome Measures

Primary Measures

  • Glucose Infusion Rate by euglycemic-hyperinsulinic clamp
    • Time Frame: 6 months

Secondary Measures

  • hepatic parameters
    • Time Frame: 6 months
  • inflammation markers
    • Time Frame: 6 months
    • IL-6, TNF alpha, CRP
  • Adipokins markers
    • Time Frame: 6 months
    • adiponectin, PAI1, leptin
  • SHBG
    • Time Frame: 6 months
  • HOMA-IR
    • Time Frame: 6 months
  • Hepatic iron overload (MRI)
    • Time Frame: 6 months
    • transaminase (ALT, AST), gamma GT
  • Abdominal and sub-cutaneous fat surface (MRI)
    • Time Frame: 6 months
  • iron parameters
    • Time Frame: at 6 months
    • serum iron, ferritin, saturation of transferrin
  • lipid profile
    • Time Frame: at 6 months
    • HDL-c, LDL-c, triglycerides

Participating in This Clinical Trial

Inclusion Criteria

  • Age between 18 and 70 years
  • Ferritin between 450 and 1000 µg/L
  • Hepatic iron overload proved by MRI (CHF >36 µmol/g)
  • Body mass index > 25 kg/m²
  • Fasting glycemia <1,26 g/L
  • HbA1c < 6,5%
  • Signed written and informed consent

Exclusion Criteria

  • Other causes of hyperferritinemia:
  • Inflammatory syndrome (CRP >10 mg/L) or inflammatory, immune or malignant diseases
  • Hyperferritinemia-cataract syndrome (familial cataract or personal history of cataract before 50 years old)
  • Low ceruloplasmin level
  • Porphyria (cutaneous signs)
  • Haemochromatosis established by the genotype (C282Y homozygous or C282Y/H63D coumpound heterozygous genotypes)
  • Contraindication of phlebotomy
  • Haemoglobin <13,5 g/dL (threshold established by the Etablissement Français du Sang)
  • Heart failure or coronary heart diseases
  • Hepatic failure, renal (GFR <50mL/min) or respiratory insufficiency (chronic dyspnea)
  • Poor venous system
  • Viral, immune, genetic, vascular, malignant or toxic chronic hepatic disease
  • Alcohol consumption more than 21 doses per week during 5 years or more
  • Type 1 or type 2 diabetes
  • Oral anti-diabetic, corticoids or immune suppressor drugs
  • Hepatic severe disease
  • Claustrophobia, having a pace-maker or intracerebral clips
  • Subjects deprived of their liberty by judicial or administrative decision, subjects that are not affiliated to social security or topics exclusion period of a previous study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rennes University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Fabrice BONNET, MD, PHD, Principal Investigator, Rennes University Hospital
    • Eric Bellissant, MD, PhD, Study Chair, RennesUniversity Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.